Keywords
Inhibidor del SGLT2
Insuficiencia renal
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the benefit and safety of using SGLT2 inhibitors in the progression of chronic kidney disease (CKD) in non-diabetic patients. Literature review: Chronic kidney disease increases the risk of cardiovascular and renal events, in addition to reducing life expectancy and quality of life. The biggest cause of CKD in the world is type 2 diabetes mellitus, which is also treated with SGLT2 inhibitors. However, there is a portion of the population that has CKD due to non-diabetic causes that also benefit from the use of this class of medications. SGLT2 inhibitors exert a renoprotective mechanism, mediated by tubuloglomerular feedback through the reduction of proximal tubular sodium reabsorption with glomerular afferent arteriolar vasoconstriction, reversing intraglomerular hypertension. There is an initial drop in renal function after the use of SGLT2 inhibitors, which is reversed in the long term with continued use of these medications. Final considerations: SGLT2 inhibitors delay the progression of chronic kidney disease and safely reduce the risks of cardiovascular mortality and renal failure in patients with CKD with or without type 2 (DM).
References
BAKRIS G, et al. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. Clinical journal of the American Society Nephrology, 2020; 15(12): 1705-1714.
CHARYTAN DM, et al. Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering. BMJ Open Diabetes Research and Care, 2023; 11(3): 003270.
CHERTOW GM, et al. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. Journal of the American Society Nephrology, 2021; 32(9): 2352-2361.
EMPA-KIDNEY COLLABORATIVE GROUP. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes and Endocrinology, 2024; 12(1): 39-50.
EMPA-KIDNEY COLLABORATIVE GROUP. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes and Endocrinology, 2024; 12(1): 51-60.
HEERSPINK HJL, et al. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney International, 2022; 101(1): 174-184.
HEERSPINK HJL, et al. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. European Heart Journal, 2021; 42(13): 1216-1227.
HEERSPINK HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. The NEW ENGLAND JOURNAL of MEDICINE, 2020; 383(15): 1436-1446.
HERRINGTON WG, et al. Cardiac, renal, and metabolic effects of sodium–glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium–glucose co-transporter 2 inhibitors. European Journal of Heart Failure, 2021; 23(8): 1260-1275.
JARDINE MJ, et al. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Journal of the American Society Nephrology, 2020; 31(5): 1128-1139.
JARDINE MJ, et al. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clinical journal of the American Society Nephrology, 2021; 16(3): 384-395.
JONGS N, et al. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD. Journal of the American Society Nephrology, 2022; 33(11): 2094-2107.
MCMURRAY JJV, et al. Effects of Dapagliflozin in Patients with Kidney Disease, With and Without Heart Failure. JACC Heart Failure, 2021; 9(11): 807-820.
MOSENZON O, et al. Dapagliflozin and Prevention of Kidney Disease Among Patients with Type 2 Diabetes: Post Hoc Analyses from the DECLARE-TIMI 58 Trial. Diabetes Care, 2022; 45(10): 2350–2359.
OSHIMA M, et al. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney International, 2020; 99(4): 999-1009.
PERKOVIC V. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The new england journal of medicine, 2019; 380(24): 2295-2306.
SHIBATA R, et al. Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus. Clinical and Experimental Nephrology, 2022; 27(1): 44-53.
THE EMPA-KIDNEY COLLABORATIVE GROUP. Empagliflozin in Patients with Chronic Kidney Disease. The new england journal of medicine, 2023; 388(2): 117-127.
VART P, et al. Efficacy and Safety of Dapagliflozin in Patients with Chronic Kidney Disease Across the Spectrum of Frailty. The Journals of Gerontology: Series A, 2023; 79(2): 181.
WAIJER SW, et al. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia, 2022; 65(7): 1085-1097.
WHEELER DC, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation, 2020; 35(10): 1700-1711.